Personalized vaccine trial aims to train immune system to fight leukemia after transplant
NCT ID NCT03679650
Summary
This early-stage trial is testing the safety of a personalized cancer vaccine for people with acute myeloid leukemia (AML) who have recently received a stem cell transplant. The vaccine is made by fusing the patient's own immune cells with their leukemia cells, aiming to teach the immune system to recognize and attack any remaining cancer. Researchers are also testing if adding a low-dose chemotherapy drug (decitabine) makes the vaccine more effective at preventing the cancer from coming back.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ACUTE MYELOGENOUS LEUKEMIA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Beth Israel Deaconess Medical Center
Boston, Massachusetts, 02215, United States
-
Dana Farber Cancer Institute
Boston, Massachusetts, 02215, United States
Conditions
Explore the condition pages connected to this study.